Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company Drug

Huadong Medicine Secures NMPA Approval for Relmapirazin Injection, Complementing MediBeacon TGFR Device

Fineline Cube Oct 17, 2025

Huadong Medicine (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has granted marketing...

Company Deals

Kexing Biopharm & Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide

Fineline Cube Oct 17, 2025

Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,...

Company Medical Device

Sinclair’s MaiLi Precise Receives NMPA Acceptance Notice for Class III Device

Fineline Cube Oct 17, 2025

Sinclair (Hangzhou) Medical Technology Co., Ltd., a wholly‑owned subsidiary of Huadong Medicine (SHE: 000963), announced...

Company Deals

I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101

Fineline Cube Oct 17, 2025

I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...

Company Drug

CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC

Fineline Cube Oct 17, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal...

Company Deals

Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia

Fineline Cube Oct 17, 2025

Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining...

Company Deals

Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates

Fineline Cube Oct 17, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of...

Company Deals

Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110

Fineline Cube Oct 17, 2025

Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial

Fineline Cube Oct 17, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...

Company

AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up

Fineline Cube Oct 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) announced a strategic re‑alignment of its respiratory inhalation portfolio in China, consolidating...

Company Deals

Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein

Fineline Cube Oct 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus Therapeutics...

Company Deals

NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed

Fineline Cube Oct 16, 2025

China‑based NeuroGen Pharma and Bocimed announced today that they have entered into an exclusive product‑transfer...

Company Drug

Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy

Fineline Cube Oct 16, 2025

Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...

Company Drug

Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC

Fineline Cube Oct 16, 2025

Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...

Company Deals

Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital

Fineline Cube Oct 16, 2025

Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...

Policy / Regulatory

Zhejiang Authority Imposes Administrative Penalties on Dahongying Pharma for Substandard Fluorouracil Injection

Fineline Cube Oct 16, 2025

The Zhejiang Provincial Medical Products Administration announced that Ningbo Dahongying Pharmaceutical Co., Ltd. has been...

Company Drug

HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI

Fineline Cube Oct 16, 2025

HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...

Company

Abbott Reports Q3 2025 Revenue of $11.369 B, Up 6.9% YoY – Strong Growth Across Nutrition & Devices Segments

Fineline Cube Oct 16, 2025

Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September 30, 2025. For...

Company Deals

Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan

Fineline Cube Oct 16, 2025

China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...

Company Deals

Genesis Healthcare & MGI Sign Strategic MOU to Accelerate Precision Medicine in Japan

Fineline Cube Oct 16, 2025

Genesis Healthcare, a leading Japanese genetic‑testing provider, today announced the signing of a Memorandum of...

Posts pagination

1 … 114 115 116 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.